A one-time therapy cannot be forecast like a recurring one. Every patient treated leaves the pool permanently, so revenue is front-loaded and finite by construction.
Newborn screening changed the shape of this market. It moved diagnosis ahead of symptom onset, which both expanded the treatable population and compressed the window in which a treatment decision is made. Sizing has to separate total prevalence from the screened, diagnosed and treated pools, because the gaps between them are where the commercial variables sit.
Gene therapy has to be modelled as a depletion curve rather than a revenue run-rate. An initial catch-up wave clears the prevalent backlog, after which volume falls to the incident birth rate. A model that extrapolates the catch-up period forward will overstate the franchise by a wide margin, and the timing of the inflection matters more to a business case than the peak figure does.
Net price, not list price, is the number that matters. A widening share of volume is paid through outcomes-based arrangements and milestone-linked annuities rather than as a single payment, so a growing proportion of patients never pay the headline figure. Modelling on list price will misstate both revenue and its timing.
With three modalities and no head-to-head trial, share cannot be read off efficacy. It follows the treatment-decision algorithm by patient type and route of administration, which is where the model has to be built.
AXLRx SMA reports size the screening funnel across the US, UK and Gulf and model the depletion curve on net price.
Zolgensma's $2.125M one-time cost, outcomes-based Medicaid contracts, and Part B vs Part D routing across three SMA modalities.
SMN1/SMN2 biology, the Type 1–4 severity spectrum, and how newborn screening splits SMA into pre-symptomatic and symptomatic populations.
Three mechanisms chase one SMN target: a one-time $2.125M gene therapy, chronic intrathecal ASO, and daily oral. Newborn screening resets the battlefield.
US SMA sizing splits into two live populations, not one number. 8,000-10,000 prevalent patients across Types 1-4, and a separate 500-700-patient Zolgensma-treated cohort now aging into a monitoring window where 15-20% show early motor plateau.
The UK SMA population is not one number. A ~1,000-patient actively-monitored NHS cohort and a 1,800-2,000-patient total prevalence estimate both appear across UK sources, and the gap between them is the pre-NBS legacy population outside the four specialist networks' active census.
All three SMA mechanisms are formulary-listed across the GCC. Outcomes-based rebate contracts now anchor Zolgensma's ~$1.5-1.8M price to a 24-month motor milestone, after an NBS expansion generating 60-80 new gene-therapy candidates a year.
The UK ran Europe's first national SMA newborn-screening programme. All three therapies are NICE-recommended with commercial arrangements, across a living UK cohort of ~1,000 patients in four disease types.
8,000-10,000 US SMA patients split roughly 60/27/13/under 5 percent across Types 1-4. The 500-700-patient Zolgensma cohort is what this funnel validates against.
All three funded SMA therapies in England reached the NHS through a conditional route. Zolgensma was recommended under HST15 and extended under HST24; nusinersen and risdiplam spent seven years in managed access before TA1162 moved them to routine commissioning.
The GCC SMA market already has three NPHC-covered agents spanning Types 1-3. A new entrant has exactly two open niches: the Zolgensma-attenuation cohort, or undiagnosed adult-onset Type 4.
Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it.
GCC SMA incidence runs 1:6,000–8,000 births, with newborn screening now covering up to 90% in leading states. An 800–1,200-patient pre-NBS-era Type 2/3 cohort defines the chronic-therapy opportunity.
SMA is the most mature rare-disease access model in the GCC. All three modalities are NPHC-covered, with Zolgensma's outcomes-based milestone rebate the GCC-first template other programmes follow.
All three SMA therapies cleared NICE with confidential PAS. The UK's 2021 newborn screening programme is now the real access lever, shifting competition to physician and family preference.
NPHC's negotiated Zolgensma price runs $1.5-1.8M against $2.125M US list. But the real mechanism is a 24-month motor-milestone rebate, the same structure now anchoring risdiplam and nusinersen pricing across the Gulf.
A mature three-drug NICE framework leaves no room for parity entry in UK SMA. The Zolgensma-attenuation and Type 4 adult niches are unserved, and NHS gene therapy centre capacity constrains every new entrant.
GCC SMA incidence runs 1:6,000-8,000 against a global 1:10,000. Newborn-screening coverage splitting 90%/85%/75% across KSA, UAE and Qatar means the addressable near-term population depends on which country's screening curve a launch model assumes.
A ~1,000-patient confirmed UK SMA cohort by type reconciles against a 1,800-2,000-patient total prevalence estimate. A 50-60/yr Zolgensma cohort is the on-therapy validation anchor.
GCC SMA incidence runs 1:6,000-8,000 births, with newborn-screening coverage from 90% down to under 50%. An 800-1,200-patient legacy Type 2/3 pool and a 60-80/yr Zolgensma cohort anchor the on-therapy view.
A fourth SMA drug has no room in the broad market — the opening is the 500–700-patient Zolgensma-attenuation cohort with no PA pathway yet.
Four designated GCC centres carry nearly all regional SMA gene-therapy and specialist referral activity. KAMC and KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi. This workbook sizes that institutional concentration before any individual name enters it.
NICE built UK SMA access in sequence, not as an open field. Gene therapy took the pre-symptomatic subgroup first (HST15, HST24), then TA1162 moved chronic therapy to routine funding behind it. A new entrant inherits a fixed subgroup hierarchy and a comparator that shifts by population.
Zolgensma's $2.125M sticker price obscures the real US SMA pricing lever. A 10-state Medicaid outcomes-based annuity pays $212,500 a year for ten years, set against chronic Spinraza and Evrysdi costs and a Part B/Part D routing split that changes patient cost by drug.
Every SMA therapy the NHS funds entered through a conditional route. Nusinersen and risdiplam sat in time-limited managed access from 2019 until TA1162 moved them to routine commissioning. UK SMA pricing is a question of how long an asset stays conditional.
SMA affects an estimated 8,000-10,000 US patients at an incidence near 1 in 10,000 live births, roughly 98% caused by biallelic SMN1 loss. GCC incidence runs higher at 1:6,000-8,000, elevated by consanguinity, producing about 300-350 new cases a year. Identification is now screening-driven: SMA joined the US Recommended Uniform Screening Panel in 2018 and all 50 states screen by 2023, catching about 300 pre-symptomatic infants a year. The UK launched the first national European programme in 2021, while GCC coverage ranges from about 90% in Saudi Arabia to under 50% in Oman, Bahrain, and Kuwait.
Newborn screening detects homozygous SMN1 deletion from a dried blood spot, then confirmatory genetic testing measures SMN1 and SMN2 copy number. SMN2 copy number sets severity across the Type 1-4 clinical spectrum, since the paralogous SMN2 gene makes a small amount of functional SMN protein. This splits the population into two commercially distinct cohorts: pre-symptomatic screening-identified infants and older symptomatic patients. Adult-onset Type 4 SMA sits outside the screening funnel, frequently misdiagnosed as limb-girdle muscular dystrophy or ALS before SMN1/SMN2 testing confirms it.
Three FDA-approved agents address the same SMN deficit by different routes. Nusinersen (Spinraza, Biogen), approved December 2016, is an intrathecal antisense oligonucleotide that modifies SMN2 splicing, with 41% motor-milestone responders versus 0% control in ENDEAR. Onasemnogene abeparvovec (Zolgensma, Novartis Gene Therapies), approved May 2019 for patients under two, is a one-time AAV9 gene therapy priced at $2.125M list, showing 91% event-free survival at 14 months in STR1VE. Risdiplam (Evrysdi, Roche/PTC Therapeutics), approved August 2020 for all ages, is a daily oral SMN2 modifier studied in FIREFISH.
We split the population before sizing it. The prevalent pool, an estimated 8,000-10,000 US patients across Types 1-4, is finite and depletes as one-time gene therapy treats it. The incident flow is what newborn screening governs: about 300 pre-symptomatic US infants a year, but only where coverage reaches them. Addressable volume therefore tracks screening penetration by geography, not raw incidence, running from roughly 90% in Saudi Arabia to under 50% in Oman, Bahrain, and Kuwait. We model each geography off its own coverage curve, run a coverage-sensitivity band, then layer a three-modality share split over the incident cohort and a depletion curve over the prevalent pool. Legacy pre-screening Type 2/3 adults, 800-1,200 in the GCC, size separately as chronic-therapy volume.
No trial compares intrathecal nusinersen, one-time Zolgensma, and oral risdiplam directly, so share cannot be read off efficacy. We model it off the treatment-decision algorithm by patient type and route preference. Pre-symptomatic screening-identified infants under two route to gene therapy, where near-normal motor development is achievable. Symptomatic Type 2/3 patients choose between intrathecal and oral, where oral risdiplam has taken roughly 50% of pediatric starts on convenience, while nusinersen retains established patients but loses new starts. We sequence share by segment and by new-start-versus-switch dynamics, then stress the split against screening timing, since earlier identification pulls more volume into the gene-therapy branch. Adult Type 4 sits outside all three algorithms.
A one-time therapy cannot be modelled like a recurring drug, because each patient treated leaves the pool permanently. We build Zolgensma volume as a depletion curve: an initial catch-up wave clearing the prevalent Type 1 backlog, then a settle to the incident birth-cohort rate that newborn screening feeds. As the backlog clears, the treatable pool shifts almost entirely to pre-symptomatic screening-identified infants under two, so long-run volume equals screened births times coverage times genetic penetrance, not prevalence. We size the durability tail separately: an estimated 500-700 US children treated between 2019 and 2023, now 4-7 years old, of whom 15-20% show early motor plateau. That attenuation cohort becomes a named addressable segment for boosters or add-on therapy.
We model net price, not list price, because a widening share of volume never pays the $2.125M headline. In the US, ten states pay through a CMS milestone-linked annuity of roughly $212,500 a year for ten years, so we build cash flows as risk-adjusted installments gated on motor milestones, not a single upfront sum. The GCC references the same precedent: a negotiated $1.5-1.8M price with a 24-month motor-milestone rebate. The comparator is cumulative chronic spend, nusinersen near $750,000 in year one then $375,000 a year, or risdiplam about $340,000 a year, so over a ten-year horizon the one-time cost is broadly comparable. We model break-even by milestone-achievement rate and payment duration, since both move the effective net price.
Each answer above draws on a specific AXLRx model. The screening-funnel sizing comes from our SMA market-sizing and patient-flow models across the US, UK, and GCC, which separate total prevalence, screening-identified incidence, and the Zolgensma-treated cohort. The three-modality share logic and the attenuation segment come from our competitive-intelligence and launch-readiness briefs. The contract economics come from our US, UK, and GCC pricing-strategy and payer-HTA models on CGTA annuities, NPHC milestone rebates, and the Long-Term Value Framework, alongside KOL mapping of the designated gene-therapy centres that gate access.